What is it about?
Deepening insulin resistance leads to the defect of estrogen synthesis and signaling, while low estrogen level or estrogen receptor defect inhibits cellular glucose uptake. Estrogen signal drives and controls all steps of cellular glucose uptake, while a defect of estrogen leads to thorough cellular defects including failure of glucose uptake.
Featured Image
Photo by Mykenzie Johnson on Unsplash
Why is it important?
Patients with insulin resistance and/or with estrogen signaling defect may be treated by insulin sensitizers and/or exogenous estrogen (oral contraceptive, postmenopausal hormone replacement) for the prevention of cancer development. Moreover, higher estrogen doses are effective even against advanced cancers.
Perspectives
We are on the route to regard estrogens as beneficial treatments against metabolic syndrome and type-2 diabetes.
professor Zsuzsanna Suba
National Institute of Oncology Budapest
Read the Original
This page is a summary of: Interplay Between Insulin Resistance and Estrogen Deficiency as co- Activators in Carcinogenesis, Pathology & Oncology Research, October 2011, Springer Science + Business Media,
DOI: 10.1007/s12253-011-9466-8.
You can read the full text:
Contributors
The following have contributed to this page
